In vitro diagnostics provider bioMérieux has entered into an agreement to acquire Specific Diagnostics, a company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures.
The company has held a minority stake in Specific Diagnostics since 2019, and the two companies had signed a co-distribution agreement covering the European market in 2021.
Antimicrobial Resistance (AMR) is a global threat, with infections from antibiotic resistant pathogens being one of the leading causes of death around the world. For clinicians to save patients’ lives and rapidly optimize therapies, fast and accurate AST results and interpretation are critical. In addition to improving patient outcomes, rapid AST also reduces global AMR burdens by enabling the implementation of effective institutional Antimicrobial Stewardship (AMS) programs.
In alignment with bioMérieux’s priority to provide innovative diagnostics to support Antimicrobial Stewardship, the Specific Reveal Rapid AST system provides actionable results for Gram-negative bacteria directly from positive blood cultures in an average of five hours. This helps clinicians to address the challenge of bloodstream infections, allowing either timely de-escalation to a focused, more appropriate, and lower-cost therapy, or life-saving rapid escalation to more effective therapy where a multidrug-resistant (MDR) infection is present.
With the addition of Rapid AST, bioMérieux’s Sepsis Solution allows same-day AST results for Gram-negative bacteria to enable more targeted therapy and improve patient outcomes.
Developed by Specific Diagnostics, and based on its unique, patented metabolomic signature technology, the Specific Reveal Rapid AST system offers an easy-to-use instrument with a targeted menu, small footprint, and modular design for adaptable throughput, well-suited to address the needs of clinical laboratories.
The addition of Specific Reveal to bioMérieux’s portfolio happens as the company recently announced the FDA approval of VITEKMS PRIME.
“This acquisition reinforces our long-standing commitment to sustain antibiotic efficacy for future generations. With the addition of Specific Diagnostics’ REVEAL Rapid AST system into our microbiology portfolio, bioMérieux further supports clinicians and laboratories in further improving patient outcomes and enhancing antimicrobial stewardship, leveraging our extensive distribution network,” says Alexandre Mérieux, chairman and CEO of bioMérieux.
For more information, visit www.biomerieux.com.